Abstract
Hepatitis C virus (HCV) infection is an important cause of liver-related morbidity and mortality in patients with end-stage renal disease (ESRD). Though indicated, antiviral therapy adds to the existing financial burden and is poorly tolerated in these patients. We studied HCV treatment outcomes in patients with moderate and severe chronic kidney disease (CKD) between June 2010 and June 2012. Out of 46 patients with CKD, only 16 (genotype 1:6, 3:9, indeterminate 1) received interferon treatment (conventional 9, pegylated 7; with low-dose ribavirin 5). End of treatment response was achieved in 50 % and sustained viral response in 44 %. Adverse effects such as tuberculosis, anemia, and cardiac failure resulting in discontinuation of therapy were seen in three. The dropout rate was 38 %. Though interferon therapy was efficacious and safe, it was received by only 35 % of patients with CKD. We suggest that antiviral therapy be offered under close monitoring in the absence of contraindications in patients with moderate and severe CKD.
This is a preview of subscription content, log in via an institution to check access.
References
Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther. 2004;20:1271–7.
Jasuja S, Gupta AK, Choudhry R, et al. Prevalence and associations of hepatitis C viremia in hemodialysis patients at a tertiary care hospital. Indian J Nephrol. 2009;19:62–7.
European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245–64.
Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29:257–6.
Fabrizi F, Lunghi G, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients. Aliment Pharmacol Ther. 2006;24:1413–22.
Deltenre P, Moreno C, Tran A, et al. Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy. Aliment Pharmacol Ther. 2011;34:454–61.
Goodkin DA, Bieber B, Gillespie B, Robinson BM, Jadoul M. Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol. 2013;38:405–12.
Stevens PE, Levin A. Kidney disease: improving global outcomes chronic kidney disease guideline development work group members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825–30.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–70.
Harris KA, Teo CG. Diversity of hepatitis C virus quasi species evaluated by denaturing gradient gel electrophoresis. Clin Diagn Lab Immunol. 2001;8:62–73.
Sezer S, Ozdemir FN, Akcay A, Arat Z, Boyacioglu S, Haberal M. Renal transplantation offers a better survival in HCV-infected ESRD patients. Clin Transplant. 2004;18:619–23.
Liu C-H, Liang C-C, Lin J-W, et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut. 2008;57:525–30.
Fabrizi F, Dixit V, Messa P, Martin P. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat. 2008;15:79–88.
Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis. 2008;51:263–77.
Rostaing L, Chatelut E, Payen JL, et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol. 1998;9:2344–8.
Liu C-H, Huang C-F, Liu C-J, et al. Pegylated Interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med. 2013;159:729–38.
Duseja A, Choudhary NS, Gupta S, Dhiman RK, Chawla Y, Sakhuja V. Treatment of chronic hepatitis C in end stage renal disease: experience at a tertiary care centre. Trop Gastroenterol. 2012;33:189–92.
Kojima A, Kakizaki S, Hosonuma K, et al. Interferon treatment for patients with chronic hepatitis C complicated with chronic renal failure receiving hemodialysis. J Gastroenterol Hepatol. 2013;28:690–9.
Conflict of interest
JR, RM, BG, PLA, JS, AG, PA, and TV declare that they have no conflict of interest.
Informed consent
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975 as revised in 2008. We did not obtain informed consent from individual patients as it was a retrospective study. Institutional ethics committee clearance was obtained.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ramachandran, J., Mahajan, R., Basu, G. et al. Efficacy and safety of hepatitis C antiviral therapy in moderate and severe chronic kidney disease. Indian J Gastroenterol 33, 471–475 (2014). https://doi.org/10.1007/s12664-014-0487-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12664-014-0487-6